Dogan Nasuh Utku, Dogan Selen, Favero Giovanni, Köhler Christhardt, Dursun Polat
Akdeniz University, Department of Obstetrics and Gynecology, Antalya, Turkey.
TÜBİTAK Research Scholar, Ankara, Turkey.
J Oncol. 2019 Jul 29;2019:3415630. doi: 10.1155/2019/3415630. eCollection 2019.
Sentinel lymph node (SLN) is the first node to receive the drainage directly from a tumor. Detection and pathological examination of the SLN is an important oncological procedure that minimizes morbidity related to extensive nodal dissection. SLN biopsy was first reported in 1960 but took approximately 40 years to come into general practice following reports of good outcomes in patients with melanoma. After many years of observation and research on its use in various malignancies SLN biopsy has become the standard surgical treatment in patients with malignant melanoma, breast, vulvar, and cervical cancers. Along with the introduction of new technologies, such as the fluorescent dyes indocyanine green (ICG) and near-infrared fluorescence (NIR), and pathologic ultrastaging, SLN detection rate has increased and false-negative rate has decreased. This literature review aimed to present an overview of the basic concepts and clinical aspects of SLN biopsy in the light of the current research.
前哨淋巴结(SLN)是首个直接接收肿瘤引流的淋巴结。前哨淋巴结的检测和病理检查是一项重要的肿瘤学程序,可将与广泛淋巴结清扫相关的发病率降至最低。前哨淋巴结活检于1960年首次报道,但在黑色素瘤患者取得良好预后的报告之后,大约花了40年才得以广泛应用。经过多年对其在各种恶性肿瘤中应用的观察和研究,前哨淋巴结活检已成为恶性黑色素瘤、乳腺癌、外阴癌和宫颈癌患者的标准手术治疗方法。随着新技术的引入,如荧光染料吲哚菁绿(ICG)和近红外荧光(NIR),以及病理超分期,前哨淋巴结的检测率有所提高,假阴性率有所降低。这篇文献综述旨在根据当前研究对前哨淋巴结活检的基本概念和临床方面进行概述。